Digital twins in pharmaceutical and process development are not a wholesale replacement for physical trials, but they function as a partial substitute, primarily for control-arm modelling, pre-trial design optimisation, and in-silico efficacy screening, with documented savings of roughly €30 million and three years of timeline in one French biotech case [S5].
Across the drug development pipeline, digital twins handle three specific tasks where physical trials are weakest: generating synthetic control arms when recruiting a real placebo cohort is unethical, modelling diverse patient subgroups that under-enrol in conventional randomised controlled trials (RCTs), and running billions of candidate-response simulations in hours rather than years [S3].
Scope: What "Process Development" Now Means for Digital Twins
The term "process development" in this context covers pharmaceutical and bioprocess development rather than discrete manufacturing, and digital twins are being deployed across the full arc from target discovery through Phase III, with the cost to sequence a human genome dropping from USD 2.7 billion in 2003 to USD 200 in 2023, a key enabler of patient-level twin construction [S3]. In a 2024 mid-year analysis of 66,935 trials, 32% of Phase II studies were terminated, a 56% increase over pre-pandemic levels, which is the operational pain point digital twin vendors are selling into [S4]. Each month of slowed enrolment adds roughly USD 500,000 in extra trial expenses and unrealised revenue, a figure that explains why sponsors are willing to fund synthetic control arm pilots even before regulators fully bless them [S1]. Industrial process control loops already consume live twin data, and a digital panel meter reading against a simulated baseline is a common hand-off point between plant-floor instrumentation and the twin's expected-value prediction.
Where Digital Twins Already Replace Physical Trials
The most concrete replacement use case is the synthetic control arm: AI-generated digital twins have been used as a proof-of-concept substitute for the standard-of-care control arm in a chronic graft-versus-host-disease trial, with the FDA signalling openness to the approach in its 2024 discussion document on in-silico evidence [S7][S3]. A second replacement class is regulatory-grade in-silico de-risking, where InSilicoTrials worked with a French biotech to simulate efficacy and safety in a market the firm had not physically trialled, yielding the cited €30 million and three-year saving, and the platform routes its simulations through more than 70 model and data partners to satisfy FDA good simulation practice expectations [S5]. The third is trial-design optimisation prior to first-patient-in: digital patient profiles built from demographics, comorbidities, severity, and concomitant medications let sponsors score investigator sites and eliminate protocol amendments that typically cost months of rework, a capability that operates before any human is dosed [S4]. This is structurally similar to how process calibration routines verify instrument accuracy against a known reference before the live measurement is trusted.
Where Physical Trials Still Cannot Be Replaced
The FDA and EMA both maintain that digital twins "do not exist to replace any clinical development processes, per se," and treat them as an enhancement to the existing toolkit rather than a substitute for first-in-human dosing, registrational safety data, or Phase IV post-marketing surveillance in underrepresented subgroups like the ORAL Surveillance tofacitinib cohort [S4][S1]. RCTs remain the gold standard because tightly controlled conditions reduce bias, but the same tightness limits external validity, which is exactly the gap twins are meant to fill, not eliminate [S1]. In open-label and rare-disease settings, twins can stand in for the control arm, but registrational decisions still require physical exposure data; the FDA's position is that twin evidence is complementary to real-world data and conventional RCTs, not a replacement pathway on its own [S2][S4]. Cell and gene therapies, where administration is restricted to a few major medical centres, illustrate the limit: even with a perfect twin, regulators need real infusion outcomes to characterise safety [S3]. For analog process signals, this is the same logic that keeps a digital multimeter on the bench: the simulation is a sanity check, not the legal record.
Comparison: Trial Use Cases Against Decision Criteria
For a sponsor choosing where to deploy a twin versus a physical study, the decision matrix lines up four use cases against four criteria: cost reduction, timeline compression, regulatory acceptability, and evidence strength. Synthetic control arms score high on cost and timeline, medium on regulatory acceptability (FDA has issued supportive guidance but no binding rule), and medium on evidence strength when used to augment rather than replace [S3][S4]. Pre-trial design optimisation scores high on cost and timeline, low on regulatory burden (it is internal), and medium on evidence strength because it produces protocol amendments rather than clinical read-outs [S4]. In-silico efficacy de-risking scores high on cost and timeline, medium on regulatory acceptability, and low-to-medium on evidence strength because regulators treat the output as hypothesis-generation [S5]. Full replacement of a Phase II or III pivotal trial scores low on regulatory acceptability and low on evidence strength under the 2024-2025 FDA and EMA posture, so this option is effectively off the table today [S4][S2]. Across process control domains, the same matrix applies: a multifunction process calibrator verifies a loop without stopping the plant, but it does not replace the loop itself.
Industrial Precedent: Where Twins Already Displaced Physical Tests
Outside pharma, the substitution case is stronger and older. Unilever used digital twins in its soap and detergent lines to cut false alerts requiring operator attention by 90%, and Citic Heavy Industries applied 3D-modelled twins to cement equipment to predict failures, saving more than 30% in operations and maintenance cost [S3]. KINEXON lifted automotive assembly line speed by 5% while reducing manual errors and product recalls through twin-driven sequencing [S3]. NASA's Apollo 13 "living model" is the canonical 1960s example, where the twin diagnosed the oxygen-tank failure and supported recovery without a physical test article, an early demonstration that a sufficiently validated model can substitute for hardware when physical testing is impossible [S3]. In each of these cases, the twin did not eliminate physical trials entirely; it removed a specific layer of physical testing where the model was demonstrably more accurate or faster than the experiment. The same logic is now being extended to v-process line simulations in foundry work, where casting parameters are validated in software before the pour.
Limitations, Failure Modes, and Open Constraints
Three constraints cap current twin capability. First, training-data representativeness: minority groups comprised less than 2% of participants in many neuro-oncology trials reviewed across 43 reports, so any twin built on that data will inherit the under-representation it is supposed to correct [S1]. Second, regulatory acceptance is uneven: the FDA's 2024 discussion document signals potential, but binding guidance for synthetic control arms in registrational trials has not been issued, and EMA positions are still being negotiated [S3][S4]. Third, twin models can drift: they must continuously update with new multi-omic and real-world data, and a stale twin is a misleading twin, which is why post-marketing Phase IV surveillance is unlikely to be replaced even as pre-Phase I work shifts in-silico [S1][S2].
Verifiable Standards and Sourcing Behind the Claims
The clinical-trial evidence base for digital twins is dominated by peer-reviewed reviews and regulatory commentary rather than binding standards; the FDA's relevant discussion document frames the technology as having "the potential to enhance drug development in many ways, including to help bring safe and effective drugs to patients faster" [S3]. The PMC review published in 2025 (cited 61 times) is the most-cited technical synthesis, and the 2026 ScienceDirect review by Venkatapurapu et al. is the most recent meta-perspective on twin-driven acceleration of drug discovery timelines [S1][S6]. Phesi's mid-2024 dataset of 66,935 trials provides the Phase II termination rate that frames the commercial case [S4], and the cost-per-month-of-delay figure of roughly USD 500,000 comes from industry analyses cited in the same review [S1].
Trackable signals to watch over the next two quarters: the FDA's next iteration of its in-silico evidence discussion document, any EMA technical guideline for synthetic control arms, and a second registrational trial in which a digital twin is used as the primary control arm rather than as supportive evidence, the milestone that would mark twins moving from supplement to substitute in the strictest sense.
For related coverage, see PVC K-value 57 vs 67 vs 70: what each grade does on a real processing line.